Xenon Pharma Executive Compensation Details Revealed
Ticker: XENE · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | DEF 14A |
| Filed Date | Apr 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, stock-options, sec-filing
TL;DR
Xenon Pharma DEF 14A shows executive stock option value changes from 2020-2024.
AI Summary
Xenon Pharmaceuticals Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation. The filing includes information on changes in the fair value of stock options for key personnel such as Simon Pimstone and Ian Mortimer, covering periods from 2020 to 2024. Specific figures related to these changes are presented within the compensation tables.
Why It Matters
This filing provides transparency into how Xenon Pharmaceuticals values and compensates its top executives, which can influence investor perception and executive retention.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of executive compensation and does not indicate any immediate financial distress or significant operational changes.
Key Numbers
- 2020-2024 — Reporting Period (Covers changes in fair value of stock options for executives)
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Filer of the DEF 14A
- Simon Pimstone (person) — Executive mentioned in compensation details
- Ian Mortimer (person) — Executive mentioned in compensation details
- 2020-01-01 (date) — Start of reporting period for compensation
- 2024-12-31 (date) — End of reporting period for compensation
FAQ
What specific dollar amounts represent the change in fair value of unvested option awards for Ian Mortimer from the prior year to the last day of 2023?
The filing indicates a change in fair value for Ian Mortimer's unvested option awards for the period of 2023-01-01 to 2023-12-31, but specific dollar amounts are detailed within the compensation tables not fully extracted here.
What was the change in fair value of option awards that vested during 2024 for Xenon Pharmaceuticals' executives?
The filing references 'ChangeInFairValueFromPriorYearsOptionAwardsThatVestedDuringTheYearMember' for the period 2024-01-01 to 2024-12-31, with specific values to be found in the detailed compensation tables.
Who are the named executive officers whose compensation is detailed in this DEF 14A filing?
The filing specifically mentions Simon Pimstone and Ian Mortimer in relation to compensation details, particularly concerning stock options.
What is the fiscal year end for Xenon Pharmaceuticals Inc. as stated in the filing?
The fiscal year end for Xenon Pharmaceuticals Inc. is December 31 (1231).
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted on April 24, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 by Simon Pimstone regarding Xenon Pharmaceuticals Inc. (XENE).